Zoono Attributes Trading Spike to Shelf-Life Extension Trials, Denies Undisclosed Info
Zoono Group Limited has responded to an ASX price query following unusual trading activity, confirming no undisclosed price-sensitive information exists and linking the movement to ongoing shelf-life extension trials with OSY Group Ltd and multiple international partners.
- Zoono denies any undisclosed material information behind recent share price and volume surge
- Ongoing shelf-life extension trials with OSY Group Ltd and multiple supermarket/packaging groups cited as cause
- 34 trials currently underway across UK, Europe, Asia, Africa, and Australia
- Most advanced trials in the UK could lead to commercial use in food packaging
- Company confirms compliance with ASX Listing Rules and continuous disclosure obligations
Context of the Price Query
On 2 May 2025, Zoono Group Limited (ASX: ZNO) addressed an official price query from ASX Compliance following a notable increase in its share price from $0.028 to $0.035 and a significant surge in trading volume. The ASX sought clarity on whether any undisclosed price-sensitive information might explain this unusual market activity.
Zoono’s Response: No Undisclosed Information
In its formal response, Zoono categorically stated it was unaware of any material information not already announced to the market that could explain the recent trading. The company reaffirmed its strict adherence to ASX Listing Rules, particularly continuous disclosure obligations under Listing Rule 3.1.
Shelf-Life Extension Trials Drive Market Interest
Zoono attributed the heightened trading activity to ongoing developments in its shelf-life extension project, conducted in partnership with OSY Group Ltd. The project involves 34 active trials with supermarket and packaging groups spanning the UK, Europe, Asia, Africa, and Australia. The most advanced trials are in the UK, where successful outcomes could pave the way for commercial adoption of Zoono and OSY’s shelf-life extension products in food packaging.
The company highlighted that these trials and ongoing discussions with participants have been previously disclosed, including in its Quarterly Report & Company Update lodged on 30 April 2025. Zoono also indicated that future agreements related to the project may be announced as they materialize, but no new contracts were disclosed at this time.
Market Implications and Compliance Assurance
By promptly addressing the ASX’s inquiries and confirming compliance with continuous disclosure rules, Zoono aims to maintain market integrity and investor confidence amid the trading volatility. The company’s transparency underscores its commitment to regulatory standards and prudent communication practices.
Investors should note that while the shelf-life extension project holds promising commercial potential, the current trading activity appears driven by anticipation rather than new material developments. The market will be watching closely for any forthcoming announcements that could crystallize the value proposition of these trials.
Bottom Line?
Zoono’s shelf-life extension trials remain the focal point for investors, with future agreements likely to shape the company’s next market move.
Questions in the middle?
- When will the ongoing shelf-life extension trials conclude, and what are the expected timelines for commercial agreements?
- What financial impact could successful shelf-life extension product adoption have on Zoono’s revenue and profitability?
- Could further trading volatility arise ahead of any formal announcements related to the shelf-life extension project?
